TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3859587
Drug: epirubicin 85
Approvals — FDA: no, EMA: no, PMDA: no
Description: epirubicin 85 mg/m2
Study: 3859587
Drug: doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxorubicin 60 mg/m2
Study: 26467038
Drug: Single-injection transversus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection transversus abdominis plane (TAP) block
Study: 23066868
Drug: Ecabet sodium
Normalized name: ecabet sodium
DrugBank: Ecabet (DB05265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecabet sodium quadruple therapy
Study: 18822996
Drug: Subsequent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent treatment options at Levels 2-4 (randomized and open label)
Study: 16125588
Drug: Intravenous artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous artesunate 2.4 mg/kg bodyweight given as a bolus at 0, 12, and 24 h, then daily
Study: 11849659
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/d for 6 weeks
Study: 11849659
Drug: Simvastatin dosage
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin dosage variations (mg/kg/day)
Study: 12202047
Drug: Risedronate (2.5‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (2.5‐ and 5‐mg doses)
Study: 9517503
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cytarabine and etoposide (HIDAC‐3‐7)
Study: 9517503
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose combination (7‐3‐7)
Study: 8791967
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg daily
Study: 8038354
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg nightly
Study: 3398651
Drug: Piroxicam cream
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam cream (0.5%, 1%, 1.5%)
Study: 3398651
Drug: Indomethacin cream
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin cream (5%)
Study: 3398651
Drug: Etofenamate gel
Normalized name: etofenamate
DrugBank: Etofenamate (DB08984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etofenamate gel (1%)
Study: 3398651
Drug: Benzydamine cream
Normalized name: benzydamine
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine cream (5%)
Study: 3398651
Drug: Piroxicam gel
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam gel (1%)
Study: 30995824
Drug: Inulin Propionate
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inulin Propionate Ester (IPE) incorporated into food products (10 g/d for six days)
Study: 25555445
Drug: Art, massage,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art, massage, or music therapy employed in hospices
Study: 21624490
Drug: BUD/FM 320/9
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/FM 320/9 μg
Study: 21624490
Drug: FP/SM 250/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/SM 250/50 μg
Study: 10934666
Drug: U.S.-brand warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: U.S.-brand warfarin sodium tablet (5 mg)
Study: 10934666
Drug: Generic warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic warfarin product (5 mg)
Study: 9795574
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education using simple line drawings of reproductive organs and signs of STDs; method not quantified in terms of dosage or duration.
Study: 1567574
Drug: Trimethoprim-sulfamethoxazole (TMP-SMX)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMX) administered at 20 mg/kg/day plus 100 mg/kg/day for 21 days.
Study: 1567574
Drug: Pentamidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentamidine administered at 4 mg/kg/day for 21 days.
Study: 1567574
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in therapy due to failure to respond.
Study: 1567574
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in therapy due to toxicity.
Study: 29031492
Drug: Comprehensive Symptom
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive Symptom Management (CSM) which combines ASM with optimized medication management delivered by a nurse-physician specialist team and facilitated mental health care
Study: 17608233
Drug: Yishen Yangnao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yishen Yangnao capsule
Study: 16125497
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers (higher doses in the upper quartile)
Study: 16125497
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers (both dosage levels)
Study: 16125497
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers (lower doses in the lower 3 quartiles)
Study: 12244291
Drug: levobupivacaine 0.50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine 0.50% (1 mg/kg)
Study: 12244291
Drug: racemic bupivacaine
Normalized name: Racemic bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: racemic bupivacaine 0.50% (1 mg/kg)
Study: 12244291
Drug: ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.75% (1.4 mg/kg)
Study: 9096446
Drug: Conventional heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional heparin
Study: 7272152
Drug: Atropine and
Normalized name: atropine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine and Metoclopramide (combined administration)
Study: 21751879
Drug: Topical N-acetyl-cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical N-acetyl-cysteine (NAC) 5%
Study: 21751879
Drug: Topical steroid-antibiotic
Normalized name: Betadine Antibiotic Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid-antibiotic combination (betamethasone 0.1%-sulfacetamide sodium 10%)
Study: 17513628
Drug: Repeat dose
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat dose of ondansetron 4 mg
Study: 9438895
Drug: Granisetron 0.1
Normalized name: granisetron 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 0.1 mg
Study: 15118190
Drug: 6.4% carbohydrate‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4% carbohydrate‐electrolyte (CHO) solution
Study: 15118190
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) solution
Study: 3182111
Drug: May and
Approvals — FDA: no, EMA: no, PMDA: no
Description: May and Baker preparation of metronidazole (200 mg)
Study: 3182111
Drug: Servipharm preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Servipharm preparation of metronidazole (200 mg)
Study: 3182111
Drug: May and
Approvals — FDA: no, EMA: no, PMDA: no
Description: May and Baker preparation of metronidazole
Study: 3182111
Drug: Servipharm preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Servipharm preparation of metronidazole
Study: 30374191
Drug: Buprenorphine/samidorphan (BUP/SAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/samidorphan (BUP/SAM) 2 mg/2 mg
Study: 23704060
Drug: Dobutamine stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine stress MR imaging (DS‐MR) at 10 μg/kg/min and 20 μg/kg/min
Study: 17990453
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with compound Reinhartdt and Sea Cumber Capsule (RSC) and Donepezil
Study: 16359481
Drug: Carboxymethyl cellulose
Normalized name: Carboxymethyl cellulose
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxymethyl cellulose (CC) adhesive paste
Study: 9820719
Drug: Low flow-rate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flow-rate (LFR) group with 2.5 L/min insufflation
Study: 9820719
Drug: High flow-rate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow-rate (HFR) group with 7.5 L/min insufflation
Study: 30375187
Drug: O-R electric
Normalized name: OSTOMY SET,STERILE O.R.GUARDIAN H#4673
Approvals — FDA: no, EMA: no, PMDA: no
Description: O-R electric toothbrush with novel round brush head (EB60) on an Oral-B Vitality O-R handle (D12)
Study: 28193616
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of betamethasone valerate 0.1% cream twice a day for 6 weeks
Study: 25297572
Drug: Glibenclamide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (2.5 mg) tablets twice daily
Study: 17053552
Drug: Spironolactone 25-50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25-50 mg once daily
Study: 15525445
Drug: Desmopressin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (0.2 microg) administered intravenously
Study: 15525445
Drug: Piroxicam administered
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam administered to achieve steady state
Study: 15525445
Drug: Desmopressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (2 microg) administered intravenously
Study: 2192099
Drug: Abana (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abana (800 mg tds)
Study: 2192099
Drug: Methyldopa (M-DOPA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (M-DOPA, 250 mg tds)
Study: 457528
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and dipyridamole premedication after 3 days
Study: 457528
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication after 3 days
Study: 31781694
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) gel applied topically on the day of frenectomy and on days 3, 7, and 14 postoperatively
Study: 31781694
Drug: No application
Approvals — FDA: no, EMA: no, PMDA: no
Description: No application of HA gel (Control)
Study: 31690647
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioural therapy (iCBT) consisting of seven weekly modules with support from a web therapist.
Study: 31690647
Drug: Care as
Normalized name: TopCare Aspirin 325mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care as usual (CAU) with no constraints regarding the range of treatments.
Study: 24220935
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg/day (oral) in repeated cycles of 4-week on/2-week off schedule
Study: 24220935
Drug: Interferon-α (IFN-α)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-α (IFN-α) 9 million units subcutaneously thrice weekly
Study: 19066303
Drug: GH bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH bolus administered postabsorptively
Study: 19066303
Drug: GH bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH bolus administered in the fasting state (37.5 h)
Study: 17469890
Drug: 8-week hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-week hypnotic taper program with self-help CBT
Study: 17469890
Drug: 8-week hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-week hypnotic taper program alone
Study: 16045027
Drug: Two-stage administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-stage administration sedation method (with propofol plus midazolam)
Study: 16045027
Drug: Routine continuum
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine continuum administration sedation method
Study: 8585734
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of ofloxacin i.v. q12h
Study: 8585734
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of ciprofloxacin i.v. q12h
Study: 8585734
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of ofloxacin i.v. q12h plus 1 g of ceftazidime i.v. q8h
Study: 8585734
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of ciprofloxacin i.v. q12h plus 1 g of ceftazidime i.v. q8h
Study: 8585734
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of ofloxacin i.v. q12h plus 4 g of piperacillin i.v. q8h
Study: 8585734
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of ciprofloxacin i.v. q12h plus 4 g of piperacillin i.v. q8h
Study: 2376426
Drug: Preparation A
Normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation A (200 mg ibuprofen)
Study: 2376426
Drug: Preparation B
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation B (200 mg ibuprofen)
Study: 6158257
Drug: Amipaque (metrizamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amipaque (metrizamide 370 mg I/ml)
Study: 6158257
Drug: Isopaque Coronar
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isopaque Coronar (metrizoate 370 mg I/ml)
Study: 30905265
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT) as part of the IAPT initiative
Study: 23590407
Drug: Experimental pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental pain model (hypertonic saline injection in infrapatellar fat pad)
Study: 23590407
Drug: Control (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (isotonic saline injection in contralateral infrapatellar fat pad)
Study: 17357053
Drug: 3-drug EFV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-drug EFV regimen (zidovudine/lamivudine plus EFV)
Study: 17357053
Drug: 4-drug EFV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-drug EFV regimen (zidovudine/lamivudine/abacavir plus EFV)
Study: 16859064
Drug: Pyridoxine (5-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (5-100 mg/day)
Study: 10759911
Drug: Zolmitriptan, 5
Normalized name: Zolmitriptan, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan, 5 mg
Study: 10849042
Drug: Rizatriptan, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan, 10 mg
Study: 8656666
Drug: cilazapril, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril, 5 mg once daily
Study: 8656666
Drug: atenolol, 100
Normalized name: Atenolol, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol, 100 mg once daily
Study: 6285721
Drug: Topical 5
Normalized name: urea topical 50% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5 percent acyclovir in polyethylene glycol
Study: 19323930
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin (80 mg simvastatin for 7 days)
Study: 11158043
Drug: Aldosterone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone (0.5 mg) after esmolol pretreatment
Study: 11158043
Drug: Aldosterone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone (0.5 mg) after dobutamine pretreatment
Study: 9576193
Drug: Intensive induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive induction and consolidation chemotherapy (4 courses)
Study: 7889896
Drug: Short-stay (SS)
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-stay (SS) group, discharged immediately (mean 18 days) for standard Health Service care at home for 6 months plus high-energy supplement (3.31 MJ with 20.6 g protein daily) for first 3 months
Study: 3225427
Drug: Intravenous cefamandole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefamandole and oral cephalexin
Study: 23212610
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous and oral)
Study: 28383710
Drug: ASP8477 (20/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP8477 (20/30 mg BID)
Study: 25257259
Drug: L-Tyrosine (TYR)
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-Tyrosine (TYR) supplement
Study: 19162114
Drug: RIX4414 co-administered
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIX4414 co-administered with OPV
Study: 19162114
Drug: Placebo co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo co-administered with OPV
Study: 10446946
Drug: Hyperglycemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia (blood glucose 9 to 11 mmol/L)
Study: 10446946
Drug: Losartan administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan administration during hyperglycemia
Study: 10446946
Drug: AngII infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AngII infusion (1.5 ng/kg per min) during hyperglycemia
Study: 17699388
Drug: AngII infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AngII infusion
Study: 10446946
Drug: Euglycemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemia (blood glucose 4 to 6 mmol/L)
Study: 11739302
Drug: Triglycerides >200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglycerides >200 mg/dL
Study: 9166835
Drug: VNCOP-B plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: VNCOP-B plus G-CSF
Study: 1586330
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (3mg) gel
Study: 28159826
Drug: Aggressive titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive titration of vasoactive HF therapies
Study: 17699177
Drug: Cardiac resynchronisation
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronisation therapy
Study: 11378012
Drug: Intravenous non-selective
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous non-selective endothelin antagonist
Study: 11378012
Drug: Etanercept (TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (TNF receptor analogue)
Study: 9131947
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose inhalation of fluticasone propionate (1000 micrograms)
Study: 9131947
Drug: Repeated inhalations
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated inhalations of fluticasone propionate (1000 micrograms twice daily for 7 days)
Study: 9131947
Drug: Intravenous dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose of fluticasone propionate (20 micrograms) as a reference
Study: 3298405
Drug: Acyclovir (ACV)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir (ACV) at 45 mg/kg/day by continuous infusion for 28 days
Study: 3298405
Drug: Acyclovir (ACV)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir (ACV) at 45 mg/kg/day by intermittent 8-hourly infusion for 28 days
Study: 3298405
Drug: Acyclovir (ACV)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir (ACV) treatment
Study: 2583756
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (120 mg elemental iron as ferrous sulphate daily)
Study: 2583756
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (240 mg elemental iron as ferrous sulphate daily)
Study: 2583756
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (60 mg elemental iron as ferrous sulphate daily)
Study: 25500684
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium valproate (20 mg/kg)
Study: 25500684
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol (5 mg/1 ml)
Study: 24001246
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management (CM) with monetary vouchers for stimulant-negative urine samples
Study: 9197957
Drug: Detergent solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detergent solutions at 37 degrees C
Study: 9197957
Drug: Detergent solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detergent solutions at 40 degrees C
Study: 17982746
Drug: Intravenous pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pethidine
Study: 4029895
Drug: Domperidone (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (equivalent dose to metoclopramide)
Study: 4029895
Drug: Metoclopramide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (20 mg) with spironolactone (300 mg/day)
Study: 4029895
Drug: Domperidone (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (equivalent dose to metoclopramide) with spironolactone (300 mg/day)
Study: 20716243
Drug: Antibiotics prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics prescribed
Study: 20716243
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics prescribed
Study: 29676944
Drug: CTS5 (Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTS5 (Clinical Treatment Score post-5 years)
Study: 27749954
Drug: Caffeine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (100 mg) plus 5 doses of 100 mL decaffeinated coffee (total 500 mg caffeine)